Trial reportClinical and translational medicine2021
Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial.
Registry-linked trialOpen access · goldAbstract readClinical TrialMulticenter Study
In one paragraph
Trial report in Clinical and translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06163833 (MATRIx), which is not on this map. Cited by 84 papers, 14 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 14 pooled it
10.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
MATRIx: MesenchymAl Stromal Cells for Traumatic bRain Injury
Who cites it
84 citing papers in PubMed, 14 syntheses or guidelines pooled it, 129 citations in OpenAlex.
- Therapeutic potential of mesenchymal stromal cells in COVID-19: a meta-analysis of clinical trials conducted since the pandemic onset.Stem cell research & therapy · 2026Pooled it
- Efficacy and safety of mesenchymal stem/stromal cells and their derived extracellular vesicles for acute respiratory distress syndrome: a systematic review and meta-analysis.Stem cell research & therapy · 2025Pooled it
- Efficacy and safety of mesenchymal stem cells therapy in COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials.Journal of translational medicine · 2024Pooled it
- Transient Fever: The Sole Treatment-Related Adverse Event Associated with Mesenchymal Stromal Cells and Solid Clues from the Real World.Current stem cell research & therapy · 2024Pooled it
- The safety and efficacy of mesenchymal stromal cells in ARDS: a meta-analysis of randomized controlled trials.Critical care (London, England) · 2023Pooled it
- Efficacy and Safety of Mesenchymal Stromal Cells Therapy for COVID-19 Infection: A Systematic Review and Meta-analysis.Current stem cell research & therapy · 2023Pooled it
- Systematic review and meta-analysis of cell therapy for COVID-19: global clinical trial landscape, published safety/efficacy outcomes, cell product manufacturing and clinical delivery.Frontiers in immunology · 2023Pooled it
- Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis.Stem cells translational medicine · 2022Pooled it
- Updated Living Systematic Review and Meta-analysis of Controlled Trials of Mesenchymal Stromal Cells to Treat COVID-19: A Framework for Accelerated Synthesis of Trial Evidence for Rapid Approval-FASTER Approval.Stem cells translational medicine · 2022Pooled it
- Safety and efficiency of stem cell therapy for COVID-19: a systematic review and meta-analysis.Global health research and policy · 2022Pooled it
- Association between Mesenchymal Stem Cells and COVID-19 Therapy: Systematic Review and Current Trends.BioMed research international · 2022Pooled it
- Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome.Frontiers in immunology · 2022Pooled it
- Effectivity of mesenchymal stem cells for bleomycin-induced pulmonary fibrosis: a systematic review and implication for clinical application.Stem cell research & therapy · 2021Pooled it
- Stem Cells Therapy for COVID-19: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Intravenous lanadelumab for the treatment of moderately ill COVID-19 patients.British journal of clinical pharmacology · 2026Trial
- Mesenchymal stromal cell therapy for COVID-19 acute respiratory distress syndrome: a double-blind randomised controlled trial.Bone marrow transplantation · 2024Trial
- Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I/II randomized, double-blind, placebo-controlled study.Stem cell research & therapy · 2024Trial
- Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial.Stem cell research & therapy · 2023Trial
- Safety of DW-MSC infusion in patients with low clinical risk COVID-19 infection: a randomized, double-blind, placebo-controlled trial.Stem cell research & therapy · 2022Trial
- Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial.Frontiers in immunology · 2022Trial
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 6 institutions in 1 country.
Xiaowei XuState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
Wanli JiangDepartment of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, Hebei, P.R. China.
Lijun ChenState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China.ORCID 0000-0001-9374-6466
Zhenyu XuInnovative Precision Medicine (IPM) Group, Hangzhou, Zhejiang, P. R. China.
Qiang ZhangInnovative Precision Medicine (IPM) Group, Hangzhou, Zhejiang, P. R. China.
Mengfei ZhuShulan (Hangzhou) Hospital, Zhejiang Shuren University Shulan International Medical College, Hangzhou, Zhejiang, P. R. China.
Peng YeDepartment of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, Hebei, P.R. China.
Hang LiInnovative Precision Medicine (IPM) Group, Hangzhou, Zhejiang, P. R. China.
Liang YuState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China.ORCID 0000-0003-1007-3951
Xiaoyang ZhouDepartment of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, Hebei, P.R. China.
Chenliang ZhouDepartment of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, Hebei, P.R. China.
Xiaobei ChenDepartment of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, Hebei, P.R. China.
Xiaoqin ZhengState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
Kaijin XuState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
Hongliu CaiState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
Shufa ZhengState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
Wubian JiangDepartment of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, Hebei, P.R. China.
Xiaojun WuDepartment of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, Hebei, P.R. China.
Dong LiDepartment of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, Hebei, P.R. China.
Lu ChenInnovative Precision Medicine (IPM) Group, Hangzhou, Zhejiang, P. R. China.
Qingqing LuoInnovative Precision Medicine (IPM) Group, Hangzhou, Zhejiang, P. R. China.
Yingyan WangInnovative Precision Medicine (IPM) Group, Hangzhou, Zhejiang, P. R. China.
Jingjing QuDepartment of Respiratory Disease, Thoracic Disease Centre, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
Yifei LiState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
Wendi ZhengState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
Yingan JiangDepartment of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, Hebei, P.R. China.
Lingling TangShulan (Hangzhou) Hospital, Zhejiang Shuren University Shulan International Medical College, Hangzhou, Zhejiang, P. R. China.
Charlie XiangState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China.ORCID 0000-0002-9193-3900
Lanjuan LiState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
Wuhan University · CNState Key Laboratory of Diagnosis and Treatment of Infectious DiseasesZhejiang Medicine (China) · CNRisun (China) · CNZhejiang Shuren University · CNFirst Affiliated Hospital Zhejiang University · CN
Funding
National Key R&D Program of China 2017YFA0105701National Natural Science Foundation of China 81802278National Natural Science Foundation of China 81900563National Science & Technology Major Project "Key New Drug Creation and Manufacturing Program" 2018ZX09201002-005the Independent Task of State Key Laboratory for Diagnosis and Treatment of Infectious Diseasesthe National Science and Technology Major Project 2017ZX10204401the Zhejiang Key Research and Development Program 2020C03125the Zhejiang Key Research and Development Program 2020C04016
Abstract
The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in December 2019 and has subsequently spread worldwide. Currently, there is no effective method to cure COVID-19. Mesenchymal stromal cells (MSCs) may be able to effectively treat COVID-19, especially for severe and critical patients. Menstrual blood-derived MSCs have recently received much attention due to their superior proliferation ability and their lack of ethical problems. Forty-four patients were enrolled from January to April 2020 in a multicenter, open-label, nonrandomized, parallel-controlled exploratory trial. Twenty-six patients received allogeneic, menstrual blood-derived MSC therapy, and concomitant medications (experimental group), and 18 patients received only concomitant medications (control group). The experimental group was treated with three infusions totaling 9 × 10
Indexed as
MenstruationMesenchymal Stem CellsMesenchymal Stem Cell TransplantationAdolescentAdultAgedAllograftsCOVID-19Critical IllnessDisease-Free SurvivalFemaleHumansMaleMiddle AgedSARS-CoV-2Severity of Illness Indexcoronavirus disease 2019 (COVID-19)mesenchymal stromal cellssafety and efficacysevere and critical patients
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT06163833ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.